Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease
A phase 3 trial of Epcoritamab, Rituximab, Lenalidomide in follicular lymphoma, run by Genmab, active and no longer recruiting.
Overview
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma is a phase 3 interventional study registered as NCT05409066 by Genmab, with 549 participants enrolled, started 2022-09-20 and due to reach its primary completion in 2029-12. Interventions recorded: Epcoritamab, Rituximab, Lenalidomide. Conditions listed: Follicular Lymphoma (FL). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease
Shares Epcoritamab, Genmab, Lenalidomide, Rituximab.
- TrialA Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refr
Shares Epcoritamab, Genmab, Follicular lymphoma.
- TrialA Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcita
Shares Epcoritamab, Genmab, Lenalidomide, Rituximab.
- TrialA Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Shares Lenalidomide, Rituximab, Follicular lymphoma.
- TrialA Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neopl
Shares Epcoritamab, Genmab, Lenalidomide, Rituximab.
- TrialTrial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
Shares Epcoritamab, Genmab, Rituximab, Follicular lymphoma.
- TrialA Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
Shares Epcoritamab, Genmab.
- TrialSafety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Shares Genmab, Lenalidomide, Rituximab, Follicular lymphoma.